<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004845</url>
  </required_header>
  <id_info>
    <org_study_id>2018-9662</org_study_id>
    <nct_id>NCT04004845</nct_id>
  </id_info>
  <brief_title>Labor Protocol Study</brief_title>
  <official_title>Effect of a Labor Induction Protocol on Vaginal Delivery Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to see if there is a better way to induce labor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is quasi-experimental prospective cohort study with historical control to examine the
      efficacy of a new labor induction bundle. The prospective cohort will consist of all eligible
      nulliparous and multiparous patients admitted for induction; the historical control group
      will consist of all eligible nulliparous and multiparous patients admitted for induction
      between August 2019 and February 2020. Patients who are part of the prospective cohort who do
      not consent to the labor bundle due to personal or physician preferences will be included in
      secondary analyses as a contemporary control group, however the sample size of this group
      will not be determined in advance.

      Objective: To assess if implementation of an evidence-based labor induction bundle will
      increase the rate of vaginal delivery within 24 hours.

      Hypothesis: Implementation of a labor induction bundle would result in a 30% increase in the
      rate of vaginal delivery within 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporarily paused due to COVID19, expected to resume. This is not a suspension of IRB approval
  </why_stopped>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 13, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Vaginal Deliveries</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Percent vaginal delivery within 24 hours of initiation of labor induction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of vaginal delivery within 12 hours of initiating induction</measure>
    <time_frame>Within 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of deliveries (vaginal or cesarean) within 12 hours of initiating induction</measure>
    <time_frame>Within 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of deliveries (vaginal or cesarean) within 24 hours of initiating induction</measure>
    <time_frame>Within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of vaginal delivery</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cesarean delivery</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of operative vaginal delivery</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients undergoing cesarean delivery, rate of each indication for cesarean delivery</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chorioamnionitis</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of vaginal exams</measure>
    <time_frame>Within 4 days</time_frame>
    <description>mean, median</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of spontaneous internal version to non-cephalic presentation</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of umbilical cord prolapse</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postpartum hemorrhage</measure>
    <time_frame>Within 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of transfusion of blood products</measure>
    <time_frame>Within 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Neonatal 5-minute APGAR score &lt;7</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Umbilical cord pH &lt; 7, &lt;7.1, &lt;7.2</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Neonatal NICU admission</measure>
    <time_frame>Within 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with induction and delivery process measured on a scale of 1-10 - immediate</measure>
    <time_frame>During delivery hospitalization</time_frame>
    <description>Will analyze mean, median. Scale 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Minimum score 1, Maximum score 10. A score of 1 is considered a worse outcome (completely dissatisfied) and 10 is considered a better outcome (completely satisfied). A score of 5 is neutral.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of shoulder dystocia</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of birth injuries (eg. brachial plexus injuries, musculoskeletal injuries, etc).</measure>
    <time_frame>Within 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of attending physicians managing induction of labor</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of attending-to-attending hand-off's</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of resident-to-resident team hand-off's</measure>
    <time_frame>Within 4 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">740</enrollment>
  <condition>Vaginal Delivery</condition>
  <condition>Labor</condition>
  <condition>Induced; Birth</condition>
  <arm_group>
    <arm_group_label>Pregnant women</arm_group_label>
    <description>We are including only women who are age 18 or over, who have a single baby (not twins), with the baby's head down, and are between 36 weeks 6 days and 42 weeks 0 days of pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytotec</intervention_name>
    <description>Misoprostol 25mcg vaginal</description>
    <arm_group_label>Pregnant women</arm_group_label>
    <other_name>misoprostol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <description>Oxytocin 10 IU/ml Solution for infusion</description>
    <arm_group_label>Pregnant women</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cervical Foley Balloon</intervention_name>
    <description>Cervical Foley will be inflated to 80cc</description>
    <arm_group_label>Pregnant women</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women with a single baby who are having their labor induced.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Singleton pregnancy

          2. Cephalic presentation

          3. Gestational age 36 weeks 6 days- 42 weeks 0 days at initiation of induction of labor

          4. Age 18 and over

        Exclusion Criteria:

          1. Preterm (less than 36 weeks 6 days) at initiation of induction of labor

          2. Non-cephalic presentation

          3. Major fetal anomalies or intrauterine fetal death

          4. Bishop score more than 6 at initiation of induction of labor

          5. Any contraindication to any agents in the induction protocol (i.e. prior cesarean
             delivery or myomectomy, three or more contractions per ten minute period averaged over
             30 minutes at the initiation of induction of labor, low lying placenta).

          6. Any contraindication to vaginal delivery

          7. Latex allergic
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bernstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center Weiler Division / Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>How HY, Leaseburge L, Khoury JC, Siddiqi TA, Spinnato JA, Sibai BM. A comparison of various routes and dosages of misoprostol for cervical ripening and the induction of labor. Am J Obstet Gynecol. 2001 Oct;185(4):911-5.</citation>
    <PMID>11641677</PMID>
  </reference>
  <reference>
    <citation>Pimentel VM, Arabkhazaeli M, Moon JY, Wang A, Kapedani A, Bernstein PS, Tropper PJ. Induction of labor using one dose vs multiple doses of misoprostol: a randomized controlled trial. Am J Obstet Gynecol. 2018 Jun;218(6):614.e1-614.e8. doi: 10.1016/j.ajog.2018.03.034. Epub 2018 Mar 31.</citation>
    <PMID>29614276</PMID>
  </reference>
  <reference>
    <citation>Macones GA, Cahill A, Stamilio DM, Odibo AO. The efficacy of early amniotomy in nulliparous labor induction: a randomized controlled trial. Am J Obstet Gynecol. 2012 Nov;207(5):403.e1-5. doi: 10.1016/j.ajog.2012.08.032. Epub 2012 Aug 24.</citation>
    <PMID>22959833</PMID>
  </reference>
  <reference>
    <citation>Wei S, Wo BL, Qi HP, Xu H, Luo ZC, Roy C, Fraser WD. Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care. Cochrane Database Syst Rev. 2013 Aug 7;(8):CD006794. doi: 10.1002/14651858.CD006794.pub4. Review.</citation>
    <PMID>23926074</PMID>
  </reference>
  <reference>
    <citation>Battarbee, A.N., Maternal and neonatal outcomes associated with early amniotomy in term nulliparous labor induction. Am J Obstet Gynecol, 2019. 220: p. 1.</citation>
  </reference>
  <reference>
    <citation>Levine LD, Downes KL, Elovitz MA, Parry S, Sammel MD, Srinivas SK. Mechanical and Pharmacologic Methods of Labor Induction: A Randomized Controlled Trial. Obstet Gynecol. 2016 Dec;128(6):1357-1364.</citation>
    <PMID>27824758</PMID>
  </reference>
  <reference>
    <citation>Mackeen AD, Durie DE, Lin M, Huls CK, Qureshey E, Paglia MJ, Sun H, Sciscione A. Foley Plus Oxytocin Compared With Oxytocin for Induction After Membrane Rupture: A Randomized Controlled Trial. Obstet Gynecol. 2018 Jan;131(1):4-11. doi: 10.1097/AOG.0000000000002374. Erratum in: Obstet Gynecol. 2018 Apr;131(4):745.</citation>
    <PMID>29215519</PMID>
  </reference>
  <reference>
    <citation>Schoen CN, Saccone G, Backley S, Sandberg EM, Gu N, Delaney S, Berghella V. Increased single-balloon Foley catheter volume for induction of labor and time to delivery: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018 Sep;97(9):1051-1060. doi: 10.1111/aogs.13353. Epub 2018 Apr 25.</citation>
    <PMID>29607491</PMID>
  </reference>
  <reference>
    <citation>Battarbee AN, Palatnik A, Peress DA, Grobman WA. Association of Early Amniotomy After Foley Balloon Catheter Ripening and Duration of Nulliparous Labor Induction. Obstet Gynecol. 2016 Sep;128(3):592-7. doi: 10.1097/AOG.0000000000001563.</citation>
    <PMID>27500341</PMID>
  </reference>
  <reference>
    <citation>Yee LM, Sandoval G, Bailit J, Reddy UM, Wapner RJ, Varner MW, Caritis SN, Prasad M, Tita AT, Saade G, Sorokin Y, Rouse DJ, Blackwell SC, Tolosa JE; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Maternal and Neonatal Outcomes With Early Compared With Delayed Pushing Among Nulliparous Women. Obstet Gynecol. 2016 Nov;128(5):1039-1047.</citation>
    <PMID>27741203</PMID>
  </reference>
  <reference>
    <citation>Cahill AG, Srinivas SK, Tita ATN, Caughey AB, Richter HE, Gregory WT, Liu J, Woolfolk C, Weinstein DL, Mathur AM, Macones GA, Tuuli MG. Effect of Immediate vs Delayed Pushing on Rates of Spontaneous Vaginal Delivery Among Nulliparous Women Receiving Neuraxial Analgesia: A Randomized Clinical Trial. JAMA. 2018 Oct 9;320(14):1444-1454. doi: 10.1001/jama.2018.13986.</citation>
    <PMID>30304425</PMID>
  </reference>
  <reference>
    <citation>Simpson LL, Rochelson B, Ananth CV, Bernstein PS, D'Alton M, Chazotte C, Lavery JA, Zielinski K; Safe Motherhood Initiative Severe Hypertension in Pregnancy Work Group . Safe Motherhood Initiative: Early Impact of Severe Hypertension in Pregnancy Bundle Implementation. AJP Rep. 2018 Oct;8(4):e212-e218. doi: 10.1055/s-0038-1673632. Epub 2018 Oct 11.</citation>
    <PMID>30319925</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists (College); Society for Maternal-Fetal Medicine, Caughey AB, Cahill AG, Guise JM, Rouse DJ. Safe prevention of the primary cesarean delivery. Am J Obstet Gynecol. 2014 Mar;210(3):179-93. doi: 10.1016/j.ajog.2014.01.026.</citation>
    <PMID>24565430</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>May 10, 2020</last_update_submitted>
  <last_update_submitted_qc>May 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Peter S. Bernstein</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

